WY 14643, A POTENT EXOGENOUS PPAR-?? LIGAND, REDUCES INTESTINAL INJURY ASSOCIATED WITH SPLANCHNIC ARTERY OCCLUSION SHOCK
- 1 October 2004
- journal article
- Published by Wolters Kluwer Health in Shock
- Vol. 22 (4) , 340-346
- https://doi.org/10.1097/01.shk.0000136704.26372.2d
Abstract
The peroxisome proliferator-activated receptor-α (PPAR-α) is a member of the nuclear receptor superfamily of ligand-dependent transcription factors related to retinoid, steroid, and thyroid hormone receptors. WY 14643 is a potent PPAR-α ligand that modulates the transcription of target genes. The aim of this study was to investigate the effect of WY 14643 on the tissue injury caused by ischemia-reperfusion (I/R) of the gut. I/R injury of the intestine was caused by clamping both the superior mesenteric artery and the celiac trunk for 45 min, followed by release of the clamp, allowing reperfusion for 2 h or 4 h. This procedure results in splanchnic artery occlusion (SAO) shock. Rats subjected to SAO developed a significant fall in mean arterial blood pressure, and only 20% of the animals survived for the entire 4-h reperfusion period. Surviving animals were sacrificed for histological examination and biochemical studies. Rats subjected to SAO displayed a significant increase in tissue myeloperoxidase (MPO) activity, significant increases in plasma tumor necrosis factor (TNF)-α and interleukin (IL)-1β levels, and marked injury to the distal ileum. Increased immunoreactivity to nitrotyrosine and polyadenosine diphosphate [ADP]-ribose (PAR) was observed in the ileum of rats subjected to SAO. Staining of sections of the ileum obtained from SAO rats with anti–intercellular adhesion molecule (ICAM-1) antibody or with anti–P-selectin antibody resulted in diffuse staining. Administration of WY 14643 (1 mg/kg i.v.) 30 min before the onset of gut ischemia significantly reduced the (a) fall in mean arterial blood pressure, (b) mortality rate, (c) infiltration of the reperfused intestine with polymorphonuclear neutrophils (MPO activity), (d) production of proinflammatory cytokines (TNF-α and IL-1β), and (e) histological evidence of gut injury. Administration of WY 14643 also markedly reduced the nitrotyrosine formation, poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) activation, up-regulation of ICAM-1, and expression of P-selectin during reperfusion. These results demonstrate that the PPAR-α agonist WY 14643 significantly reduces I/R injury of the intestine.Keywords
This publication has 29 references indexed in Scilit:
- Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusionCardiovascular Research, 2004
- Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-γ ligand, on lung ischemia-reperfusion injury in ratsEuropean Journal of Cardio-Thoracic Surgery, 2004
- Peroxisome proliferator-activated receptor-α regulates postischemic liver injuryAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2004
- Role of peroxisome proliferator-activated receptor-γ in the protection afforded by 15-deoxyΔ12,14 prostaglandin J2 against the multiple organ failure caused by endotoxinCritical Care Medicine, 2004
- Pioglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Attenuates Myocardial Ischemia/Reperfusion Injury in a Rat ModelLaboratory Investigation, 2003
- Activation of Peroxisome Proliferator–Activated Receptor-α Protects the Heart From Ischemia/Reperfusion InjuryCirculation, 2003
- Fibrates down-regulate IL-1–stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB–C/EBP-β complex formationBlood, 2003
- Beneficial Effects Of GPI 6150, an Inhibitor of Poly(ADP-Ribose) Polymerase in a Rat Model of Splanchnic Artery Occlusion and ReperfusionShock, 2002
- Negative Regulation of Human Fibrinogen Gene Expression by Peroxisome Proliferator-activated Receptor α Agonists via Inhibition of CCAAT Box/Enhancer-binding Protein βJournal of Biological Chemistry, 2001
- PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancerTrends in Pharmacological Sciences, 2000